{"id":38727,"date":"2025-10-20T11:04:59","date_gmt":"2025-10-20T09:04:59","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/?p=38727"},"modified":"2025-10-17T11:41:35","modified_gmt":"2025-10-17T09:41:35","slug":"neue-analysen-zu-doak-bei-alteren-und-gebrechlichen-mit-nicht-valvularem-vorhofflimmern-cme","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2025\/neue-analysen-zu-doak-bei-alteren-und-gebrechlichen-mit-nicht-valvularem-vorhofflimmern-cme","title":{"rendered":"Neue Analysen zu DOAK bei \u00c4lteren und Gebrechlichen mit nicht-valvul\u00e4rem Vorhofflimmern [CME]"},"content":{"rendered":"<p>Etwa 20% der &gt;\u00a080-J\u00e4hrigen haben nicht-valvul\u00e4res Vorhofflimmern (Vofli;\u00a0). Vitamin\u00a0K-Antagonisten (VKA) verhindern Schlaganf\u00e4lle wirksam, relativ um etwa 64% . Bei multimorbiden, \u00e4lteren Patienten mit vielen Begleitmedikamenten und eingeschr\u00e4nkter Arzneimittel-Clearance kommen Blutungskomplikationen, einschlie\u00dflich intrazerebraler Blutungen (ICB), geh\u00e4uft vor ,\u00a0. Aus Unsicherheit wurde \u00e4lteren Patienten \u2013 trotz eindeutiger Indikation \u2013 eine orale Antikoagulation (OAK) mitunter vorenthalten oder mit [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Etwa 20% der &gt;\u00a080-J\u00e4hrigen haben nicht-valvul\u00e4res Vorhofflimmern (Vofli;\u00a0). Vitamin\u00a0K-Antagonisten (VKA) verhindern Schlaganf\u00e4lle wirksam, relativ um etwa 64% . Bei multimorbiden, \u00e4lteren Patienten mit vielen Begleitmedikamenten und eingeschr\u00e4nkter Arzneimittel-Clearance kommen Blutungskomplikationen, einschlie\u00dflich intrazerebraler Blutungen (ICB), geh\u00e4uft vor ,\u00a0. Aus Unsicherheit wurde \u00e4lteren Patienten \u2013 trotz eindeutiger Indikation \u2013 eine orale Antikoagulation (OAK) mitunter vorenthalten oder mit [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[185,6263,349,1322,4379,6261,2305,1314,1312,2068,2067,6262,5923,187,1328,1327,138,2727,183,2304,54,51,181,136],"class_list":["post-38727","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-absolute-arrhythmie","tag-aconvenience-studie","tag-alter","tag-apixaban","tag-aristotle-studie","tag-combine-af-studie","tag-dabigatran","tag-direkte-orale-antikoagulanzien","tag-doak","tag-edoxaban","tag-engage-af-timi-48-studie","tag-frail-af-studie","tag-gebrechlichkeit","tag-herzrhythmusstoerungen","tag-neue-orale-antikoagulanzien","tag-noak","tag-phenprocoumon","tag-re-ly-studie","tag-rhythmusstoerungen","tag-rivaroxaban","tag-thromboembolie","tag-thrombose","tag-vorhofflimmern","tag-warfarin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/38727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=38727"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/38727\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=38727"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=38727"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=38727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}